183 related articles for article (PubMed ID: 23611064)
1. Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital.
Chin PK; Vella-Brincat JW; Walker SL; Barclay ML; Begg EJ
Intern Med J; 2013 Jul; 43(7):778-83. PubMed ID: 23611064
[TBL] [Abstract][Full Text] [Related]
2. Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayers.
Ishiguro N; Kishimoto W; Volz A; Ludwig-Schwellinger E; Ebner T; Schaefer O
Drug Metab Dispos; 2014 Feb; 42(2):250-6. PubMed ID: 24212377
[TBL] [Abstract][Full Text] [Related]
3. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.
Kishimoto W; Ishiguro N; Ludwig-Schwellinger E; Ebner T; Schaefer O
Drug Metab Dispos; 2014 Feb; 42(2):257-63. PubMed ID: 24212378
[TBL] [Abstract][Full Text] [Related]
4. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN).
Van de Werf F; Brueckmann M; Connolly SJ; Friedman J; Granger CB; Härtter S; Harper R; Kappetein AP; Lehr T; Mack MJ; Noack H; Eikelboom JW
Am Heart J; 2012 Jun; 163(6):931-937.e1. PubMed ID: 22709744
[TBL] [Abstract][Full Text] [Related]
5. Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C.
Chin PK; Wright DF; Zhang M; Wallace MC; Roberts RL; Patterson DM; Jensen BP; Barclay ML; Begg EJ
Drugs R D; 2014 Jun; 14(2):113-23. PubMed ID: 24797400
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.
Stangier J; Stähle H; Rathgen K; Roth W; Shakeri-Nejad K
J Clin Pharmacol; 2008 Dec; 48(12):1411-9. PubMed ID: 18827075
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis.
Eriksson BI; Dahl OE; Rosencher N; Clemens A; Hantel S; Kurth AA
Thromb Res; 2012 Dec; 130(6):871-6. PubMed ID: 22995531
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.
Friedman RJ; Kurth A; Clemens A; Noack H; Eriksson BI; Caprini JA
Thromb Haemost; 2012 Jul; 108(1):183-90. PubMed ID: 22552763
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands.
Postma MJ; Kappelhoff BS; van Hulst M; Brouwers JR
J Med Econ; 2012; 15(5):878-86. PubMed ID: 22563715
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.
Stangier J; Eriksson BI; Dahl OE; Ahnfelt L; Nehmiz G; Stähle H; Rathgen K; Svärd R
J Clin Pharmacol; 2005 May; 45(5):555-63. PubMed ID: 15831779
[TBL] [Abstract][Full Text] [Related]
12. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
[TBL] [Abstract][Full Text] [Related]
13. Dabigatran: new drug. Continue to use heparin, a better-known option.
Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation.
Lehr T; Haertter S; Liesenfeld KH; Staab A; Clemens A; Reilly PA; Friedman J
J Clin Pharmacol; 2012 Sep; 52(9):1373-8. PubMed ID: 21956604
[TBL] [Abstract][Full Text] [Related]
15. The pharmacology and therapeutic use of dabigatran etexilate.
Sarah S
J Clin Pharmacol; 2013 Jan; 53(1):1-13. PubMed ID: 23400738
[TBL] [Abstract][Full Text] [Related]
16. Rash associated with dabigatran etexilate.
To K; Reynolds C; Spinler SA
Pharmacotherapy; 2013 Mar; 33(3):e23-7. PubMed ID: 23400964
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial.
Liesenfeld KH; Lehr T; Dansirikul C; Reilly PA; Connolly SJ; Ezekowitz MD; Yusuf S; Wallentin L; Haertter S; Staab A
J Thromb Haemost; 2011 Nov; 9(11):2168-75. PubMed ID: 21972820
[TBL] [Abstract][Full Text] [Related]
18. Hemopericardium in a patient treated with dabigatran etexilate.
Barton CA; McMillian WD; Raza SS; Keller RE
Pharmacotherapy; 2012 May; 32(5):e103-7. PubMed ID: 22488474
[TBL] [Abstract][Full Text] [Related]
19. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
Eisert WG; Hauel N; Stangier J; Wienen W; Clemens A; van Ryn J
Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):1885-9. PubMed ID: 20671233
[TBL] [Abstract][Full Text] [Related]
20. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Aug; 98(2):333-8. PubMed ID: 17721615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
